CJC-1295 (no DAC)
Modified GRF 1-29 · GHRH analog
Overview
CJC-1295 without DAC (also known as Modified GRF 1-29 or ModGRF 1-29) is a 29-amino-acid GHRH analog with four amino-acid substitutions (Tyr1→D-Ala, Ala8→Gln, Ala15→Ala, Met27→Leu) that confer protection against DPP-4 cleavage and serum protease degradation. The molecule signals through the GHRH receptor to produce pulsatile GH release that closely resembles physiological secretion patterns, distinct from the more sustained drug-affinity-complex (DAC) version, which has substantially longer plasma half-life via covalent albumin binding. Lyochem supplies CJC-1295 no-DAC as the acetate salt, lyophilized, ≥99.0% HPLC. The no-DAC form is most commonly paired with a GHSR-pathway agonist (Ipamorelin, GHRP-2, or GHRP-6) in GH-axis research and compounding workflows, the dual-pathway combination produces additive GH-release signals beyond either component alone, and the canonical CJC-1295 + Ipamorelin blend is one of the most-requested SKUs in our catalog (sold as the dedicated cjc-1295-ipamorelin combination vial). For the full pharmacology rationale of the dual-pathway combination, see our [CJC-1295 + Ipamorelin guide](/lab-notes/cjc-1295-ipamorelin-blend-pharmacology-guide). Compounding pharmacies typically dispense from 2 mg or 5 mg vials; research labs often prefer the 5 mg or 10 mg fills for in vivo dose-titration work.
Who buys this, and why
GH-axis peptides ship to research labs studying somatotropic-pathway pharmacology, IGF-axis signalling, and pulse vs. sustained-elevation GH biology. Buyers qualifying a new source typically request sequence verification on the first lot, the counter-ion form (acetate by default), and stability data at −20 °C. Blends — the CJC-1295 + Ipamorelin co-formulated lot is the canonical example — are co-lyophilised rather than solution-mixed so the ratio is locked at the lyophilisation step.
Primary buyer fit: academic and contract research laboratories and research laboratories that have validated this peptide into their workflow.
Specifications
- CAS
- 863288-34-0 (DAC form has same CAS-class but distinct identifier, confirm via COA)
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 2 mg, 5 mg, 10 mg
- MOQ
- On request
- Lead time
- 7–14 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Counter-ion analysis (acetate vs TFA)
- Stability at −20 °C across 12 months
- Solubility in BAC water / PBS reconstitution
Regulatory note
Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration, and not supplied to compounding pharmacies — Lyochem's GH-axis lots are scoped to research workflows only. Buyers studying somatotropic pharmacology should specify the counter-ion form (acetate by default) and any pulse-vs-sustained study design notes at quote stage.
Frequently asked questions
What's the difference between CJC-1295 with DAC and without DAC?▾
Both are based on the same Modified GRF 1-29 core sequence, but the DAC (Drug Affinity Complex) version has a maleimido-propionyl-Lys30 modification that allows covalent binding to serum albumin, dramatically extending plasma half-life from minutes (no-DAC) to roughly a week (DAC). The clinical/research consequence is fundamentally different pharmacokinetic profiles: the no-DAC form produces pulsatile GH release that mimics physiological secretion patterns, while the DAC form produces a sustained elevation that suppresses the natural pulse architecture. Most compounding pharmacy and physiological-research workflows use the no-DAC form; the DAC form is more common in sustained-elevation research contexts.
Why is CJC-1295 almost always combined with Ipamorelin in practice?▾
CJC-1295 signals through the GHRH receptor; Ipamorelin signals through the GHSR (ghrelin receptor). These are two parallel input pathways that both drive somatotroph GH release, and they synergize rather than compete, combining a GHRH-pathway agonist with a GHSR-pathway agonist produces GH-release magnitudes larger than either component alone at comparable individual doses. The standard ratio for the combined product is 1:1 by mass (most commonly 2+2 mg or 5+5 mg per vial). Lyochem supplies pre-blended co-lyophilized vials under the cjc-1295-ipamorelin SKU, which is preferred over the buyer mixing the two in solution because the analytical packet certifies the actual ratio in the released vial.
How is CJC-1295 typically reconstituted and stored after opening?▾
Lyophilized CJC-1295 reconstitutes cleanly in bacteriostatic water for injection at typical research and compounding concentrations. The reconstituted solution is reasonably stable when held at -20 °C as single-use aliquots, but degradation accelerates with freeze-thaw cycling, the operational guidance for the GH-axis class is to aliquot immediately into the smallest workable single-use volumes and limit thaw cycles to three or fewer. The lyophilized vial itself follows the standard 24-month re-test window at -20 °C; the COA carries a documented re-test date for buyers planning recurring orders.
Related peptides
Buyers who view CJC-1295 (no DAC) also ask about:
Ipamorelin
≥99.0%Ghrelin / GHSR pathway GH-release peptide
- CAS
- 170851-70-4
- Vial
- 2 mg–10 mg
CJC-1295 + Ipamorelin
≥99.0%GH-axis blend (CJC-1295 no DAC + Ipamorelin)
- CAS
- —
- Vial
- 10 mg
29-mer
Sermorelin
≥99.0%GHRH 1-29 fragment
- CAS
- 86168-78-7
- Vial
- 2 mg–10 mg
CJC-1295 with DAC
≥99.0%Long-acting GHRH analog with Drug Affinity Complex
- CAS
- 863288-34-0
- Vial
- 2 mg · 5 mg